Effects of open-label atomoxetine on African-American and Caucasian pediatric outpatients with attention-deficit/hyperactivity disorder

Annals of Clinical Psychiatry

Volumn 21, Issue 1, 2009, Pages 26-37

  Durell, Todd M ^a   Pumariega, Andres J ^b   Rothe, Eugenio M ^c   Tamayo, Jorge M ^d,e   Baron, David ^f   Williams, David ^a  

^a ELI LILLY AND COMPANY   (United States)

^b READING HOSPITAL AND MEDICAL CENTER   (United States)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^d UNIVERSIDAD CES   (Colombia)

^e UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^f TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

African American; Atomoxetine; Attention deficit hyperactivity disorder; Caucasian; Race

Indexed keywords

ADRENERGIC RECEPTOR AFFECTING AGENT; ATOMOXETINE; PROPYLAMINE;

AFRICAN AMERICAN; AMBULATORY CARE; ARTICLE; ATTENTION DEFICIT DISORDER; CAUCASIAN; CHEMICALLY INDUCED DISORDER; CHILD; CLINICAL TRIAL; DRUG EFFECT; DRUG TOLERANCE; FATIGUE; FEMALE; HEART RATE; HUMAN; HYPERTENSION; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; QUESTIONNAIRE; STATISTICS; TREATMENT OUTCOME; VOMITING;

ADRENERGIC UPTAKE INHIBITORS; AFRICAN AMERICANS; AMBULATORY CARE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DRUG TOLERANCE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FATIGUE; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; PATIENT COMPLIANCE; PROPYLAMINES; QUESTIONNAIRES; TREATMENT OUTCOME; VOMITING;

EID: 67650155369     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Centers for Disease Control and Prevention. Mental health in the United States: prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder-United States, 2003. MMWR Morb Mortal Wkly Rep. 2005;54(34):842-847.
2. Rappley MD. Attention deficit-hyperactivity disorder. N Engl J Med. 2005;352(2):165-173. (Pubitemid 40096613)
3. Bazargan M, Calderon JL, Heslin KC, et al. A profile of chronic mental and physical conditions among African-American and Latino children in urban public housing. Ethn Dis. 2005;15(suppl 5):S53-S59.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000.
5. American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000;105(5):1158-1170.
6. Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry. 1991;148(5):564-577.
7. Brown RT, Borden KA. Hyperactivity at adolescence: some misconceptions and new directions. J Clin Child Psychol. 1986;15(3):194-209.
8. Hechtman L. Assessment and diagnosis of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2000;9(3):481-498. (Pubitemid 30620539)
9. Klein RG, Mannuzza S. Long-term outcome of hyperactive children: a review. J Am Child Adolesc Psychiatry. 1991;30(3):383-387.
10. Thorley G. Review of follow-up and follow-back studies of childhood hyperactivity. Psychol Bull. 1984;96(1):116-132.
11. Bussing R, Zima BT, Gary FA, et al. Barriers to detection, help-seeking, and service use for children with ADHD symptoms. J Behav Health Serv Res. 2003;30(2):176-189. (Pubitemid 36397440)
12. Stevens J, Harman JS, Kelleher KJ. Race/ethnicity and insurance status as factors associated with ADHD treatment patterns. J Child Adolesc Psychopharmacol. 2005;15(1):88-96. (Pubitemid 40365918)
13. Olfson M, Gameroff MJ, Marcus SC, et al. National trends in the treatment of attention deficit hyperactivity disorder. Am J Psychiatry. 2003;160(6):1071- 1077.
14. Arnold LE, Elliott M, Sachs L, et al. Effects of ethnicity on treatment attendance, stimulant response/ dose, and 14-month outcome in ADHD. J Consult Clin Psychol. 2003;71(4):713-727. (Pubitemid 36897405)
15. Davison JC, Ford DY. Perceptions of attention deficit hyperactivity disorder in one African-American community. J Negro Educ. 2001;70(4):264-274.
16. Bailey RK, Owens DL. Overcoming challenges in the diagnosis and treatment of attention-deficit/hyperactivity disorder in African Americans. J Natl Med Assoc. 2005;97(10 suppl):5S-10S. (Pubitemid 41429049)
17. Bussing R, Schoenberg NE, Perwien AR. Knowledge and information about ADHD: evidence of cultural differences among African-Americans and White parents. Soc Sci Med. 1998;46(7):919-928. (Pubitemid 28102492)
18. Bussing R, Schoenberg NE, Rogers KM, et al. Explanatory models of ADHD: do they differ by ethnicity, child gender, or treatment status? J Emot Behav Disord. 1998;6(4):233-242.
19. Dosreis S, Butz A, Lipkin PH, et al. Attitudes about stimulant medication for attention-deficit/hyperactivity disorder among African American families in an inner city community. J Behav Health Serv Res. 2006;33(4):423-430. (Pubitemid 44786664)
20. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention- deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114(1):e1-e8.
21. Michelson D, Buitelaar JK, Danckaerts M, et al. Relapse prevention in pediatric patients with ADHD treatment with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2004;43(7):896-904. (Pubitemid 38808495)
22. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63(12):1140-1147. (Pubitemid 36084059)
23. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112-120. (Pubitemid 36126473)
24. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of atomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1998;155(5):693-695. (Pubitemid 28225414)
25. Starr HL, Kemner J. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD. J Natl Med Assoc. 2005;97(suppl):11S-16S. (Pubitemid 41429050)
26. DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale-IV: Checklist, Norms, and Clinical Interpretations. New York, NY: Guilford Press; 1998.
27. Tamayo JM, Pumariega A, Rothe EM, et al. Latino versus Caucasian response to atomoxetine in attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2008;18:44-53. (Pubitemid 351313821)
28. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADSPL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36(7):980-988. (Pubitemid 27272932)
29. Kumar G, Steer RA. Factorial validity of the Conners' Parent Rating Scale-Revised: Short Form with psychiatric outpatients. J Pers Assess. 2003;80(3):252-259. (Pubitemid 36724248)
30. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003;26(10):729-740. (Pubitemid 36976134)
31. Zito JM, Safer DJ, dosReis S, et al. Methylphenidate patterns among Medicaid youths. Psychopharmacol Bull. 1997;33(1):143-147. (Pubitemid 27184209)
32. Lipkin PH, Cozen MA, Thompson RE, et al. Stimulant dosage and age, race, and insurance type in a sample of children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharm. 2005;15(2):240-248. (Pubitemid 40734103)
33. Steele M, Jensen PS, Quinn DM. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther. 2006;28:1892-1908. (Pubitemid 46038524)